全基因组测序揭示原发性膜增生性肾小球肾炎与C3肾小球病的遗传架构
该研究对146例原发性膜增生性GN和6442例欧洲裔对照进行全基因组测序分析,未发现补体基因罕见变异显著富集,但鉴定出6p21.32 HLA位点常见变异与疾病显著关联,并验证了特定HLA单倍型。结论挑战补体基因突变通常导致原发性MPGN的范式,提示多数病例存在自身免疫机制。
要点
- 原发性MPGN中补体基因罕见变异未见显著富集(6.8% vs 5.9%)。
- HLA位点常见变异rs35406322与原发性MPGN显著关联(OR 1.93)。
- 特定HLA单倍型(DQA1*05:01-DQB1*02:01-DRB1*03:01)关联更强(OR 2.19)。
核心结论
- HLA类型而非补体基因罕见变异与原发性膜增生性GN相关。
- 研究结果挑战补体基因突变通常导致原发性MPGN的范式,提示多数病例存在自身免疫机制。
研究设计与样本
- 研究分析165例原发性MPGN病例和10250例对照的全基因组测序数据,来自NIHR BioResource-Rare Diseases Study。
- 最终分析纳入146例无亲缘关系的欧洲裔原发性MPGN病例和6442例对照。
主要发现
- 候选基因(补体替代途径组分及aHUS相关基因)罕见变异在病例中占6.8%,对照中占5.9%,无显著富集。
- 全外显子组范围未见罕见变异显著富集。
- 鉴定出6p21.32(rs35406322)常见变异显著关联(P=3.29×10-8;OR=1.93;95%CI 1.53-2.44),重叠HLA位点。
- HLA类型插补将信号定位至包含DQA1*05:01、DQB1*02:01和DRB1*03:01的单倍型(P=1.21×10-8;OR=2.19;95%CI 1.66-2.89)。
- 在338例MPGN和15614例非免疫性肾衰竭个体中分析HLA血清型,重复验证了该发现。
关键数值与推荐
- 候选基因罕见变异频率:病例6.8% vs 对照5.9%(无显著差异)。
- rs35406322关联:P=3.29×10-8;OR=1.93;95%CI 1.53-2.44。
- HLA单倍型关联:P=1.21×10-8;OR=2.19;95%CI 1.66-2.89。
临床怎么用
- 原发性MPGN/C3肾小球病患者的遗传评估应关注HLA区域常见变异而非仅补体基因罕见变异。
- HLA单倍型DQA1*05:01-DQB1*02:01-DRB1*03:01可能提示自身免疫机制参与,支持免疫相关诊疗思路。
局限性
- 研究仅纳入欧洲裔无亲缘关系个体,结果外推至其他种族需谨慎。
- 样本量有限(146例病例),罕见变异分析效能可能不足。
- HLA血清型重复验证使用非免疫性肾衰竭对照,对照组选择可能影响结果解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Primary membranoproliferative GN, including complement 3 (C3) glomerulopathy, is a rare, untreatable kidney disease characterized by glomerular complement deposition. Complement gene mutations can cause familial C3 glomerulopathy, and studies have reported rare variants in complement genes in nonfamilial primary membranoproliferative GN. METHODS: We analyzed whole-genome sequence data from 165 primary membranoproliferative GN cases and 10,250 individuals without the condition (controls) as part of the National Institutes of Health Research BioResource-Rare Diseases Study. We examined copy number, rare, and common variants. RESULTS: Our analysis included 146 primary membranoproliferative GN cases and 6442 controls who were unrelated and of European ancestry. We observed no significant enrichment of rare variants in candidate genes (genes encoding components of the complement alternative pathway and other genes associated with the related disease atypical hemolytic uremic syndrome; 6.8% in cases versus 5.9% in controls) or exome-wide. However, a significant common variant locus was identified at 6p21.32 (rs35406322) (P=3.29×10-8; odds ratio [OR], 1.93; 95% confidence interval [95% CI], 1.53 to 2.44), overlapping the HLA locus. Imputation of HLA types mapped this signal to a haplotype incorporating DQA1*05:01, DQB1*02:01, and DRB1*03:01 (P=1.21×10-8; OR, 2.19; 95% CI, 1.66 to 2.89). This finding was replicated by analysis of HLA serotypes in 338 individuals with membranoproliferative GN and 15,614 individuals with nonimmune renal failure. CONCLUSIONS: We found that HLA type, but not rare complement gene variation, is associated with primary membranoproliferative GN. These findings challenge the paradigm of complement gene mutations typically causing primary membranoproliferative GN and implicate an underlying autoimmune mechanism in most cases.
引用
- Levine AP, Chan MMY, Sadeghi-Alavijeh O, et al. Large-Scale Whole-Genome Sequencing Reveals the Genetic Architecture of Primary Membranoproliferative GN and C3 Glomerulopathy. J Am Soc Nephrol. 2020. PMID: 31919107. doi:10.1681/ASN.2019040433
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。